scholarly journals “Kawasaki disease shock syndrome in the COVID-19 pandemic”

2021 ◽  
pp. 1-8
Author(s):  
Luisa B. Gámez-González ◽  
Moises J. Ramírez-López ◽  
Marcela Colmenero-Rascón ◽  
Marco A. Yamazaki-Nakashimada
Keyword(s):  
Kawasaki Disease ◽  
Diagnostic Criteria ◽  
Clinical Features ◽  
Unique Form ◽  
Representative Case ◽  
Inflammatory Syndrome

Abstract Multisystem Inflammatory Syndrome in Children (MIS-C) is a new entity with association with SARS-CoV2. Clinical features of Kawasaki disease (KD) were noted from the first reported cases of MIS-C. Before the COVID-19 pandemic, Kawasaki disease shock syndrome (KDSS) was considered to be a distinct and unique form of KD. We present a representative case which prove the current difficulty in clearly distinguishing MIS-C from Pre-COVID-19-KDSS and emphasize the overlap of the diagnostic criteria.

scholarly journals COVID-19 Inflammatory Syndrome With Clinical Features Resembling Kawasaki Disease

PEDIATRICS ◽  
2020 ◽  
Vol 146 (3) ◽  
pp. e20201845
Author(s):  
Robert Spencer ◽  
Ryan C. Closson ◽  
Mark Gorelik ◽  
Alexis D. Boneparth ◽  
Rebecca F. Hough ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Clinical Features ◽  
Inflammatory Syndrome

scholarly journals Multisystem Inflammatory Syndrome due to COVID-19 in a Newborn Patient: A Case Report from Lebanon

2021 ◽  
Vol 2 (1) ◽  
pp. 30-36
Author(s):  
Haidar Houmani ◽  
Narjes Hazimeh ◽  
Oussama Skafi ◽  
Fawziya Medlej ◽  
Fatima Ahmad ◽  
...  
Keyword(s):  
Case Report ◽  
Kawasaki Disease ◽  
Diagnostic Criteria ◽  
Toxic Shock Syndrome ◽  
Fatality Rate ◽  
Toxic Shock ◽  
Therapeutic Guidelines ◽  
The World ◽  
Inflammatory Syndrome ◽  
Rate Case

Background: Multisystem inflammatory syndrome in children (MIS-C) is a hyperinflammatory condition associated with COVID-19 in children, with features that are similar to Kawasaki disease and toxic shock syndrome. Several reports are emerging from all over the world on this condition that is associated with increased fatality rate. Case Report: In this article, we present one of the first reports of a newborn diagnosed with MIS-C attributed to COVID-19. In addition, we discuss the diagnostic criteria and the possible pathophysiology. Conclusion: Although COVID-19 does not frequently affect newborns, when it does, it may lead to devastating complications, such as MIS-C. As a result, providers should be on the lookout for any symptoms that can indicate a complicated infection. Further studies are still needed to develop a better understanding of the pathophysiology of this disease and establish appropriate therapeutic guidelines.

scholarly journals Similarities and Differences Between COVID-19-Related Multisystem Inflammatory Syndrome in Children and Kawasaki Disease

2021 ◽  
Vol 9 ◽  
Author(s):  
Min-Sheng Lee ◽  
Yi-Ching Liu ◽  
Ching-Chung Tsai ◽  
Jong-Hau Hsu ◽  
Jiunn-Ren Wu
Keyword(s):  
United States ◽  
Differential Diagnosis ◽  
Kawasaki Disease ◽  
Clinical Features ◽  
Toxic Shock Syndrome ◽  
The United States ◽  
Toxic Shock ◽  
First Case ◽  
Similarities And Differences ◽  
Inflammatory Syndrome

In December 2019, the first case of coronavirus disease (COVID-19) was first reported in Wuhan, China. As of March 2021, there were more than 120 million confirmed cases of COVID-19 and 2.7 million deaths. The COVID-19 mortality rate in adults is around 1–5%, and only a small proportion of children requires hospitalization and intensive care. Recently, an increasing number of COVID-19 cases in children have been associated with a new multisystem inflammatory syndrome. Its clinical features and laboratory characteristics are similar to those of Kawasaki disease (KD), KD shock syndrome, and toxic shock syndrome. However, this new disorder has some distinct clinical features and laboratory characteristics. This condition, also known as multisystem inflammatory syndrome in children (MIS-C) associated with COVID-19, has been observed mostly in Europe and the United States. This emerging phenomenon has raised the question of whether this disorder is KD triggered by SARS-CoV-2 or a syndrome characterized by multisystem inflammation that mimics KD. This narrative review is to discuss the differences between MIS-C and KD with the aim of increasing pediatricians' awareness of this new condition and guide them in the process of differential diagnosis.

scholarly journals Clinical features and disease severity in patients with mosaic neurofibromatosis type 1: a single-center study and literature review

2021 ◽  
Vol 16 (1) ◽  
Author(s):  
C. Ejerskov ◽  
M. Raundahl ◽  
P. A. Gregersen ◽  
M. M. Handrup
Keyword(s):  
Cognitive Impairment ◽  
Learning Disability ◽  
Diagnostic Criteria ◽  
Clinical Features ◽  
Neurofibromatosis Type 1 ◽  
Plexiform Neurofibroma ◽  
Neurofibromatosis Type ◽  
Language Delay

Abstract Background The mosaic form of neurofibromatosis type 1 (NF1) is called mosaic NF1 (MNF1). No specific MNF1 follow-up guidelines exist. It is debatable if patients with MNF1 should be clinically examined and undergo follow-up in accordance with the standard NF1 guidelines, as MNF1 patients more often may develop more benign phenotypes and thereby less disease-associated complications including cognitive impairment. We discussed the need for a specific MNF1 follow-up guideline with focus on frequency of plexiform neurofibromas and NF1-associated complications. Method A systematic retrospective data collection in a MNF1 cohort from one of two Danish national centers of NF1 Expertise was completed. Data collected included demographics, clinical features including NF1 diagnostic criteria and NF1-associated complications. Recent literature in the field was reviewed. Results We identified 17 patients with MNF1 with a median age of 37 years [4; 66]. Eleven (65%) were females. Five patients (30%) had a plexiform neurofibroma. The median age at detection of plexiform neurofibroma was 30 years [14; 60]. Nine (53%) had at least one NF1-related complication; scoliosis, hypertension, ADHD, learning disability, language delay, autism and delay in gross and fine motor function development. We reviewed nine articles. In total, 126 cases were described within three case-series. Nineteen (15%) had a plexiform neurofibroma and in total, 23 NF1-associated complications were reported including language delay, learning disability and skeletal abnormalities. Furthermore, from the literature it was evident that the diagnosing of MNF1 varies among physicians and across countries. Conclusion Patients with MNF1 present with plexiform neurofibromas and other NF1-related complications with a frequency requiring that follow-up of MNF1 patients should be in accordance with the standard NF1 guideline in both childhood and adulthood. Physicians should be aware of cognitive impairment as a complication to MNF1. To develop a specific MNF1 follow-up guideline, there is a need for an international consensus on the diagnostic criteria for MNF1 and a follow-up study conducted in a larger MNF1 cohort.

scholarly journals Diversity of Cardiac and Gastrointestinal Presentations of Multisystem Inflammatory Syndrome in Children (MIS-C) Associated with COVID-19: A Case Series

2021 ◽  
Vol 8 ◽  
pp. 2333794X2199661
Author(s):  
Anuja R. Shikhare ◽  
Rimsha M. Iqbal ◽  
Rabail Tariq ◽  
Daniel R. Turner ◽  
Bassam M. Gebara ◽  
...  
Keyword(s):  
Kawasaki Disease ◽  
Gastrointestinal Symptoms ◽  
Case Series ◽  
Asymptomatic Infection ◽  
Cardiac Monitoring ◽  
Delayed Presentation ◽  
Terminal Ileitis ◽  
Serologic Evidence ◽  
Cardiac Manifestations ◽  
Inflammatory Syndrome

COVID-19 is generally a benign or asymptomatic infection in children, but can occasionally be severe or fatal. Delayed presentation of COVID-19 with hyperinflammation and multi-organ involvement was recently recognized, designated the Multisystem Inflammatory Syndrome in Children (MIS-C). Six children with MIS-C with molecular and serologic evidence of SARS-CoV-2 infection were admitted to our hospital between May 5, 2020 and June 25, 2020. All had fever and weakness; 4/6 presented with gastrointestinal symptoms. Two children had features of complete Kawasaki disease, 3 had incomplete Kawasaki disease, while 1 had terminal ileitis with delayed onset of circulatory shock. Treatment consisted of intravenous immunoglobulin and aspirin for Kawasaki-like disease. Remdesivir, corticosteroids, and infliximab were used when indicated. Median hospitalization was 7 days. Immediate treatment resulted in rapid clinical improvement. In children presenting with hyperinflammatory syndromes without cardiac manifestations, testing for SARS-CoV-2 RNA and antibodies, with close cardiac monitoring should be pursued due to the manifold presentations of SARS-CoV-2 infection in children.

Sign in / Sign up

Export Citation Format

Share Document